Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer

Carolien K. M. Vermeulen*, Workineh Tadesse, Maite Timmermans, Roy F. P. M. Kruitwagen, Tom Walsh

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)100-105
Number of pages6
JournalEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
Volume219
DOIs
Publication statusPublished - Dec 2017

Keywords

  • Epithelial ovarian cancer
  • Cytoreductive surgery
  • Debulking surgery
  • Neoadjuvant chemotherapy
  • Survival
  • GRADE SEROUS CARCINOMA
  • PRIMARY SURGERY
  • INTERVAL DEBULKING
  • CYTOREDUCTIVE SURGERY
  • STAGE IV
  • METAANALYSIS
  • VALIDATION
  • PROGNOSIS
  • SURVIVAL
  • SYSTEM

Cite this